misuse and abuse of prescription opioids ( such as oxycodone ) , which are used to treat both acute and chronic pain , has become a serious public health problem in the united states , including among medicare beneficiaries .
in this report , we: 1. describe how medicare identifies beneficiaries at risk of opioid misuse and abuse , and how it attempts to mitigate that risk ; 2. identify factors likely to affect the success of the medicare drug management programs .
in april 2018 , the centers for medicare & medicaid services ( cms ) , which administers the medicare program , finalized regulations implementing dmps for part d medicare's prescription drug option , through which private health insurers known as plan sponsors provide prescription drug coverage to medicare beneficiaries .
for medicare , the comprehensive addiction and recovery act of 2016 ( cara ) established drug management programs ( dmp ) to limit access to frequently abused drugs for beneficiaries considered to be at risk for their abuse , among other things .
the centers for disease control and prevention ( cdc ) reported that from 1999 to 2013 the rate of deaths from prescription opioids nearly quadrupled .